Tag: allergy

蘇黎世, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI 於格拉斯哥舉行的 2025 年度大會上啟動了抗生素過敏意識宣傳活動。 此倡議開創了一項全球行動，以解決錯誤標籤問題及其與抗微生物劑耐藥性 (AMR) 的關聯。

ZURICH, 15 août 2025 (GLOBE NEWSWIRE) -- L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 à Glasgow. Cette initiative marque le début d’un effort mondial visant à lutter contre les erreurs d’étiquetage et son lien avec la résistance aux antimicrobiens (RAM).

The global allergy diagnostics market, poised to reach USD 11.63 billion by 2030, is expanding at a CAGR of 10.39% from 2025. The rise in allergies highlights the need for precise diagnostics. Major players like Thermo Fisher and Siemens are innovating to meet demand. Key growth regions include North America and Asia Pacific.

The global allergy diagnostics market, poised to reach USD 11.63 billion by 2030, is expanding at a CAGR of 10.39% from 2025. The rise in allergies highlights the need for precise diagnostics. Major players like Thermo Fisher and Siemens are innovating to meet demand. Key growth regions include North America and Asia Pacific.

Introduction of TRUBAR™ Kids Line in Sprouts Farmers Market marks brand's entry into the kids snack bar market with the highest fiber and protein content...

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The global Suppositories Market, valued at US$1.56 billion in 2024 stood at US$1.63 billion in 2025 and...

[Ad hoc announcement pursuant to Art. 53 LR]

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...